304 related articles for article (PubMed ID: 27521306)
1. Prognosis of Primary Myelofibrosis in the Genomic Era.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
[TBL] [Abstract][Full Text] [Related]
2. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Loscocco GG; Rotunno G; Mannelli F; Coltro G; Gesullo F; Pancani F; Signori L; Maccari C; Esposito M; Paoli C; Vannucchi AM; Guglielmelli P
Am J Hematol; 2024 Jan; 99(1):68-78. PubMed ID: 37846894
[TBL] [Abstract][Full Text] [Related]
3. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Horvat NP; Abdallah EF; Xie Z; Al Ali N; Yun S; Walker A; Padron E; Sallman D; Chan O; Lancet J; Komrokji R; Kuykendall AT
Ann Hematol; 2024 Jan; 103(1):117-123. PubMed ID: 38030891
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.
Mahmud M; Vasireddy S; Gowin K; Amaraneni A
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139212
[TBL] [Abstract][Full Text] [Related]
5. Momelotinib therapy for myelofibrosis: a 7-year follow-up.
Tefferi A; Barraco D; Lasho TL; Shah S; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Cancer J; 2018 Mar; 8(3):29. PubMed ID: 29515114
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
Wang Z; Liu W; Wang M; Li Y; Wang X; Yang E; Ming J; Quan R; Hu X
Ann Hematol; 2021 Feb; 100(2):465-479. PubMed ID: 33386934
[TBL] [Abstract][Full Text] [Related]
7. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
Aguirre LE; Jain A; Ball S; Ali NA; Volpe VO; Tinsley-Vance S; Sallman D; Sweet K; Lancet J; Padron E; Yun S; Kuykendall A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38548563
[TBL] [Abstract][Full Text] [Related]
8. Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.
Gilani JA; Ashfaq MA; Mansoor AE; Abdul Jabbar A; Siddiqui T; Khan M
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1691-1699. PubMed ID: 31244289
[TBL] [Abstract][Full Text] [Related]
9. Leukemic conversion involving
Gurban P; Mambet C; Botezatu A; Necula LG; Neagu AI; Matei L; Pitica IM; Nedeianu S; Chivu-Economescu M; Bleotu C; Ataman M; Mocanu G; Saguna C; Pavel AG; Stambouli D; Sepulchre E; Anton G; Diaconu CC; Constantinescu SN
Front Oncol; 2023; 13():1266996. PubMed ID: 37841434
[TBL] [Abstract][Full Text] [Related]
10. Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.
Skov V
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781570
[TBL] [Abstract][Full Text] [Related]
11. [Pathogenic role of insufficiency of polycomb repressive complex in primary myelofibrosis].
Shinoda D
Rinsho Ketsueki; 2023; 64(9):998-1006. PubMed ID: 37793876
[TBL] [Abstract][Full Text] [Related]
12. Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest.
Mondet J; Hussein K; Mossuz P
Mediators Inflamm; 2015; 2015():670580. PubMed ID: 26525644
[TBL] [Abstract][Full Text] [Related]
13. Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis.
Parenti S; Rontauroli S; Carretta C; Mallia S; Genovese E; Chiereghin C; Peano C; Tavernari L; Bianchi E; Fantini S; Sartini S; Romano O; Bicciato S; Tagliafico E; Della Porta M; Manfredini R
NPJ Precis Oncol; 2021 Feb; 5(1):4. PubMed ID: 33542466
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune myelofibrosis: A Mayo Clinic series of 22 patients.
Gangat N; Reichard K; Orazi A; Tefferi A
Br J Haematol; 2024 May; ():. PubMed ID: 38698680
[TBL] [Abstract][Full Text] [Related]
15. [A case of prefibrotic primary myelofibrosis in a child with type-Ⅰ CALR gene mutation].
Li SQ; Zhao YQ; Zhao XL; Wang XG; Li SB; Song LL; Zhou YJ; Zang WT; Hao T; Yao XJ
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):928-930. PubMed ID: 37803861
[TBL] [Abstract][Full Text] [Related]
16. Risk models in myelofibrosis-the past, present, and future.
Tefferi A; Vannucchi AM
Am J Hematol; 2024 Apr; 99(4):519-522. PubMed ID: 38400565
[TBL] [Abstract][Full Text] [Related]
17. Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.
Guerra M; Pasquer H; Daltro de Oliveira R; Soret-Dulphy J; Maslah N; Zhao LP; Marcault C; Cazaux M; Gauthier N; Verger E; Parquet N; Vainchenker W; Raffoux E; Giraudier S; Cassinat B; Kiladjian JJ; Benajiba L
Am J Hematol; 2024 Apr; 99(4):741-744. PubMed ID: 38279562
[TBL] [Abstract][Full Text] [Related]
18. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
19. Primary myelofibrosis and its targeted therapy.
Shantzer L; Berger K; Pu JJ
Ann Hematol; 2017 Apr; 96(4):531-535. PubMed ID: 27539616
[TBL] [Abstract][Full Text] [Related]
20. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
